2-hoba for treatment of pulmonary hypertension
Ended Project Grant Awarded Last action
- Award ID
- R41HL158393
- Recipient
-
MTI Biotech, Incorporated UEI N5NDNJL8QGA1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,026,320
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Funding
-
- $769,740.00 Federal
- $256,580.00 Non-federal
- Place of performance
- Ames, IA 50010, USA
Award details come from USAspending.gov.
Description
- Abstract
- Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactivation of the mitochondrial lysine deacetylase SIRT3 is a central node in regulating the metabolic defects. A vicious cycle exists in which a triggering event or mutation increases reactive oxygen species (ROS), which produces reactive lipids, which adduct and inactivate SIRT3, causing metabolic changes that result in further increased ROS. Here, we break this cycle using 2-hoba, a small molecule which can effectively soak up reactive lipids in vivo and has positive results in safety trials for other indications in humans, with some still ongoing. Effectiveness of 2-hoba has already been established for the prevention of PH in mice, and the mechanism suggests IT should be effective for reversal. Here, we prepare for human trials of 2-hoba by testing its efficacy for reversal of established disease in two molecularly accurate mouse models alone or in combination with metformin, and by examining serum biomarkers of disease shared between humans and mice for early indications of response which can be used to guide human trials.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $256,580 | $0 | |
| Amendment | $256,580 | $0 | |
| Amendment | $256,580 | $256,580 | |
| Amendment | -$256,580 | $0 | |
| Amendment | -$256,580 | $0 | |
| Amendment | -$256,580 | -$256,580 | |
| Amendment | $256,580 | $0 | |
| Amendment | $256,580 | $0 | |
| Original award | $256,580 | $256,580 |
Show all 12
Quick answers
Who received award R41HL158393?
R41HL158393 was awarded to MTI Biotech, Incorporated by National Heart Lung and Blood Institute (National Institutes of Health) on August 1, 2021.
How much is award R41HL158393 worth?
$1,026,320 has been obligated on R41HL158393: $769,740 in federal funding and $256,580 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award